Topline Data On Wegovy's Impact On Cardiovascular Outcomes
Topline data from the SELECT trial look good. But this may not necessarily change payer coverage policies on weight loss agents, at least not in the short term.
Source: forbes.com
Page 2 - Select Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Select Trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Select Trial Today - Breaking & Trending Today
SELECT Trial Shows Semaglutide 2.4 mg Could Reduce Cardiovascular Risk
Novo Nordisk has announced topline data from the SELECT trial, which suggest use of once-weekly semaglutide 2.4 mg was associated with a statistically significant 20% reduction in 3-point MACE among a cohort with overweight or obesity and established cardiovascular disease.
Source: hcplive.com
GLP-1 RAs and the Evolving Role of Cardiologists in Obesity Management, with Michael Blaha, MD
In a recent Q&A, Michael Blaha, MD, discusses how he views the ideal role of cardiologists in the management of obesity and how this role could change based on the results of the SELECT trial.
Source: hcplive.com
Quality of Life and Real-World Data in Patients With RR DTC
Expert perspectives on real world and quality of life data behind systemic therapy in patients with radioiodine-refractory differentiated thyroid cancer.
Source: onclive.com
Overview of Available Treatment Options for RR DTC
Expert oncologists work together to review the treatment armamentarium for radioiodine-refractory differentiated thyroid cancer and identify factors that best inform selection of therapy.
Source: onclive.com